Exact Mass: 710.3795

nudicauline

C38H50N2O11 (710.3414)

Origin: Plant; SubCategory_DNP: Terpenoid alkaloids, Diterpene alkaloid, Delphinium alkaloid

Strophanthin

C36H54O14 (710.3513)

D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D013328 - Strophanthins D002317 - Cardiovascular Agents D004791 - Enzyme Inhibitors

Boivinide A

C36H54O14 (710.3513)

Atractyloside H

C32H54O17 (710.3361)

(3b,16a,20R)-25-Acetoxy-3,16,20,22-tetrahydroxy-5-cucurbiten-11-one 3-glucoside

C38H62O12 (710.4241)

(3b,16a,20R)-25-Acetoxy-3,16,20,22-tetrahydroxy-5-cucurbiten-11-one 3-glucoside is found in fruits. (3b,16a,20R)-25-Acetoxy-3,16,20,22-tetrahydroxy-5-cucurbiten-11-one 3-glucoside is a constituent of Cyclanthera pedata (achoccha) Constituent of Cyclanthera pedata (achoccha). (3b,16a,20R)-25-Acetoxy-3,16,20,22-tetrahydroxy-5-cucurbiten-11-one 3-glucoside is found in fruits.

Strophanthin

C36H54O14 (710.3513)

D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D013328 - Strophanthins D002317 - Cardiovascular Agents D004791 - Enzyme Inhibitors

Andersoline

C38H50N2O11 (710.3414)

PA(13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C38H63O10P (710.4159)

PA(13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of Resolvin D5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/13:0)

C38H63O10P (710.4159)

PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/13:0), in particular, consists of one chain of one Resolvin D5 at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C38H63O10P (710.4159)

PA(13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of Protectin DX at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/13:0)

C38H63O10P (710.4159)

PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/13:0), in particular, consists of one chain of one Protectin DX at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(a-13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C38H63O10P (710.4159)

PA(a-13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of Resolvin D5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/a-13:0)

C38H63O10P (710.4159)

PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/a-13:0), in particular, consists of one chain of one Resolvin D5 at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(a-13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C38H63O10P (710.4159)

PA(a-13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of Protectin DX at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/a-13:0)

C38H63O10P (710.4159)

PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/a-13:0), in particular, consists of one chain of one Protectin DX at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C38H63O10P (710.4159)

PA(i-13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of Resolvin D5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/i-13:0)

C38H63O10P (710.4159)

PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/i-13:0), in particular, consists of one chain of one Resolvin D5 at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C38H63O10P (710.4159)

PA(i-13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of Protectin DX at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/i-13:0)

C38H63O10P (710.4159)

PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/i-13:0), in particular, consists of one chain of one Protectin DX at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

Geyerline

C38H50N2O11 (710.3414)

Myrtucommulone H

C41H58O10 (710.403)

Elephanoside A

C38H62O12 (710.4241)

Coproporphyrin III tetramethyl ester

C40H46N4O8 (710.3315)

MEGxp0_000987

C38H62O12 (710.4241)

(3β,8ξ,9ξ,14ξ,16ξ,17ξ,20ξ,22ξ)-Spirostan-3-yl 6-O-β-D-xylopyranosyl-β-D-galactopyranoside

C38H62O12 (710.4241)

Gluco-lanadoxin

C36H54O14 (710.3513)

C38H62O12

C38H62O12 (710.4241)

C37H58O13

C37H58O13 (710.3877)

meliavolin

C41H58O10 (710.403)

6alpha-O-[beta-D-xylopyranosyl-(1->3)-beta-D-quinovopyranosyl]-(25S)-5alpha-spirostan-3-beta-ol

C38H62O12 (710.4241)

sarmutogenin glucosyl-diginoside

C36H54O14 (710.3513)

25-O-methyl-7-beta-hydroxy-24-O-acetylhydroshengmanol-3-O-beta-D-xylopyranoside

C38H62O12 (710.4241)

Jatropha factor C4

C44H54O8 (710.3818)

25-O-methyl-1-alpha-hydroxy-24-O-acetylhydroshengmanol-3-O-beta-D-xylopyranoside

C38H62O12 (710.4241)

Jatropha factor C3

C44H54O8 (710.3818)

Jatropha factor C2

C44H54O8 (710.3818)

(1beta,3beta,5beta,25S)-spirostan-1,3-diol 1-[alpha-L-rhamnopyranosyl-(1->2)-beta-D-xylopyranoside]|1-O-alpha-L-rhamnopyranosyl-(1-2)-beta-D-xylopyranoside of rhodeasapogenin

C38H62O12 (710.4241)

Delta16-8beta-hydroxydigitoxigenin beta-odorobioside

C36H54O14 (710.3513)

24-epi-24-O-acetylhydroshengmanol-3-O-beta-D-galactopyranoside

C38H62O12 (710.4241)

C36H54O14

C36H54O14 (710.3513)

C39H50O12

C39H50O12 (710.3302)

jatropha factor C6

C44H54O8 (710.3818)

(4R,4aS,5R,6S,8aS,9aR)-2,4,4a,5,6,7,8,8a,9,9a-decahydro-4-hydroxy-8a-({(4R,4aS,5R,6S,8aS,9aR)-2,4,4a,5,6,7,8,8a,9,9a-decahydro-8a-hydroxy-3,4a,5-trimethyl-6-[(3-methylbut-2-enoyl)oxy]-2-oxonaphtho[2,3-b]furan-4-yl}oxy)-3,4a,5-trimethyl-2-oxonaphtho[2,3-b]furan-6-yl (2E)-2-methylbut-2-enoate|hertidin E

C40H54O11 (710.3666)

(22R,24S,31S)-22,31-epoxy-1alpha,3beta,24-trihydroxy-31-methoxy-24-methyl-9beta,19-cyclolanostan-28-oic acid beta-D-glucopyranosyl ester|(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl (1alpha,3beta,4alpha,5alpha,9beta,28S)-1,3,24-trihydroxy-28-methoxy-4,14-dimethyl-22,28-epoxy-9,19-cycloergostane-4-carboxylate|(31S)-31-O-methylpassiflorine

C38H62O12 (710.4241)

(3S,6Z,9S,12S,18S,23aS)-18-(1-hydroxyethyl)-3-(hydroxymethyl)-6-[(1H-indol-3-yl)methylidene]-12-methyl-9-(2-methylpropyl)hexadecahydro-1H-pyrrolo[1,2-a] [1,4,7,10,13,16,19]heptaazacyclohenicosine-1,4,7,10,13,16,19-heptone|cyclo-(Pro1-Ser2-Delta-Trp3-Leu4-Ala5-Gly6-Thr7)|tunicyclin G

C34H46N8O9 (710.3388)

mandelalide B

C37H58O13 (710.3877)

Erycorchosid|Eryperosid

C36H54O14 (710.3513)

C46H59ClO4

C46H59ClO4 (710.4102)

jatropha factor C1

C44H54O8 (710.3818)

C40H54O11

C40H54O11 (710.3666)

25-(acetyloxy)-2-(beta-D-glucopyranosyloxy)-3,16,20-trihydroxy-9-methyl-19-norlanost-5-en-22-one

C38H62O12 (710.4241)

(+) hebridamine|Hebridamine

C42H50N2O8 (710.3567)

erythrophlesin A

C41H58O10 (710.403)

3,4-dimethoxy pycnocomolide|3,4-Dimethoxy-Pycnocomolide|3,4-dimethoxypycnocomolide

C43H50O9 (710.3455)

3-beta-[(O-beta-D-glucopyranosyl-(1->3)-4,6-dideoxy-2-O-methyl-beta-D-gulopyranosyl)]-5beta,14beta-dihydroxy-19-oxocard-20(22)enolide

C36H54O14 (710.3513)

1,1-diacetyl-[15,15]biaspidospermidinyl-16,17,16,17-tetraol

C42H54N4O6 (710.4043)

[17-(2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl)-3-hydroxy-4,4,9,13,14-pentamethyl-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-16-yl] acetate

C38H62O12 (710.4241)

Nudicaulinea

C38H50N2O11 (710.3414)

C36H54O14_Card-20(22)-enolide, 3-[(2,6-dideoxy-4-O-beta-D-glucopyranosyl-3-O-methyl-beta-D-ribo-hexopyranosyl)oxy]-5,14-dihydroxy-19-oxo-, (3beta,5beta)

C36H54O14 (710.3513)

C38H62O12_beta-D-Galactopyranoside, (3beta,8xi,9xi,14xi,16xi,17xi,20xi,22xi)-spirostan-3-yl 6-O-beta-D-xylopyranosyl

C38H62O12 (710.4241)

C36H54O14_Card-20(22)-enolide, 3-[(6-deoxy-4-O-hexopyranosyl-3-O-methylhexopyranosyl)oxy]-14-hydroxy-19-oxo

C36H54O14 (710.3513)

[17-(2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl)-3-hydroxy-4,4,9,13,14-pentamethyl-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-16-yl] acetate

C38H62O12 (710.4241)

[17-(2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl)-3-hydroxy-4,4,9,13,14-pentamethyl-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-16-yl] acetate [IIN-based: Match]

C38H62O12 (710.4241)

[17-(2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl)-3-hydroxy-4,4,9,13,14-pentamethyl-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-16-yl] acetate [IIN-based on: CCMSLIB00000847647]

C38H62O12 (710.4241)

[17-(2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl)-3-hydroxy-4,4,9,13,14-pentamethyl-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-16-yl] acetate_major

C38H62O12 (710.4241)

MELYR

C31H50N8O9S (710.3421)

(3b,16a,20R)-25-Acetoxy-3,16,20,22-tetrahydroxy-5-cucurbiten-11-one 3-glucoside

C38H62O12 (710.4241)

PHDdiA-PG

C34H63O13P (710.4006)

3-O(4-O-beta-D-glucopyranosyl-alpha-L-rhamnopyranosyl)-3beta,14beta,16beta-trihydroxy-5beta-bufa-20,22-dienolide

C36H54O14 (710.3513)

Kondensationsprodukte von Dicarbonsuren mit mehrwertigen aliphatischen Alkoholen verestert

C38H62O12 (710.4241)

Butacaine sulfate

C36H62N4O8S (710.4288)

gd(tmhd)3

C33H60GdO6 (710.3631)

21H,23H-Porphine-2,7,12,17-tetrapropanoicacid, 3,8,13,18-tetramethyl-, 2,7,12,17-tetramethyl ester

C40H46N4O8 (710.3315)

PA(13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C38H63O10P (710.4159)

PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/13:0)

C38H63O10P (710.4159)

PA(13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C38H63O10P (710.4159)

PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/13:0)

C38H63O10P (710.4159)

PA(a-13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C38H63O10P (710.4159)

PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/a-13:0)

C38H63O10P (710.4159)

PA(a-13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C38H63O10P (710.4159)

PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/a-13:0)

C38H63O10P (710.4159)

PA(i-13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C38H63O10P (710.4159)

PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/i-13:0)

C38H63O10P (710.4159)

PA(i-13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C38H63O10P (710.4159)

PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/i-13:0)

C38H63O10P (710.4159)

Strophanthin K

C36H54O14 (710.3513)

D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D013328 - Strophanthins

3beta-[(O-beta-D-Glucopyranosyl-(1->3)-4,6-dideoxy-2-O-methyl-beta-D-gulopyranosyl)]-5beta,14beta-dihydroxy-19-oxocard-20(22)enolide

C36H54O14 (710.3513)

A cardenolide glycoside that is strophanthidin attached to a 4,6-dideoxy-3-O-(beta-D-glucopyranosyl)-2-O-methyl-beta-D-xylo-hexopyranosyl residue at position 3 via a glycosidic linkage. Isolated from Crossosoma bigelovii, it exhibits cytotoxic activity.

[(1S,2S,4S,5R,6S,8R,9R,10R,13S,16S,18S)-6-acetyloxy-11-ethyl-8,9-dihydroxy-4,16,18-trimethoxy-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-13-yl]methyl 2-[(3S)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate

C38H50N2O11 (710.3414)

Smgdg O-9:0_17:1

C35H66O12S (710.4275)

Smgdg O-17:1_9:0

C35H66O12S (710.4275)

Smgdg O-18:1_8:0

C35H66O12S (710.4275)

Smgdg O-24:1_2:0

C35H66O12S (710.4275)

Smgdg O-22:1_4:0

C35H66O12S (710.4275)

Smgdg O-21:1_5:0

C35H66O12S (710.4275)

Smgdg O-8:0_18:1

C35H66O12S (710.4275)

Smgdg O-19:1_7:0

C35H66O12S (710.4275)

Smgdg O-20:1_6:0

C35H66O12S (710.4275)

Smgdg O-13:0_13:1

C35H66O12S (710.4275)

Smgdg O-10:0_16:1

C35H66O12S (710.4275)

Smgdg O-12:0_14:1

C35H66O12S (710.4275)

Smgdg O-15:1_11:0

C35H66O12S (710.4275)

Smgdg O-14:1_12:0

C35H66O12S (710.4275)

Smgdg O-16:1_10:0

C35H66O12S (710.4275)

Smgdg O-11:0_15:1

C35H66O12S (710.4275)

Smgdg O-13:1_13:0

C35H66O12S (710.4275)

[1-Acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] heptadecanoate

C34H62O15 (710.4089)

[1-Heptanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] dodecanoate

C34H62O15 (710.4089)

[1-Pentanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] tetradecanoate

C34H62O15 (710.4089)

[1-Octanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] undecanoate

C34H62O15 (710.4089)

[1-Propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] hexadecanoate

C34H62O15 (710.4089)

[1-Nonanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] decanoate

C34H62O15 (710.4089)

[1-Hexanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] tridecanoate

C34H62O15 (710.4089)

[1-Butanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] pentadecanoate

C34H62O15 (710.4089)

[6-(3-Dodecanoyloxy-2-tetradecanoyloxypropoxy)-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C35H66O12S (710.4275)

[6-[2,3-Di(tridecanoyloxy)propoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C35H66O12S (710.4275)

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C38H63O10P (710.4159)

[1-[[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C38H63O10P (710.4159)

[1-[[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C38H63O10P (710.4159)

[1-[(2-decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C38H63O10P (710.4159)

[1-hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-nonadec-9-enoate

C34H63O13P (710.4006)

[1-heptanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-octadec-9-enoate

C34H63O13P (710.4006)

[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-henicos-11-enoate

C34H63O13P (710.4006)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-icos-11-enoate

C34H63O13P (710.4006)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-nonanoyloxypropan-2-yl] (Z)-hexadec-9-enoate

C34H63O13P (710.4006)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-octanoyloxypropan-2-yl] (Z)-heptadec-9-enoate

C34H63O13P (710.4006)

[1-dodecanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-tridec-9-enoate

C34H63O13P (710.4006)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C38H63O10P (710.4159)

[1-decanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-pentadec-9-enoate

C34H63O13P (710.4006)

[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxypropyl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C38H63O10P (710.4159)

[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropyl] (9Z,12Z)-hexadeca-9,12-dienoate

C38H63O10P (710.4159)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (Z)-tetradec-9-enoate

C34H63O13P (710.4006)

[1-decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C38H63O10P (710.4159)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-docos-13-enoate

C34H63O13P (710.4006)

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C41H58O10 (710.403)

[(2S,3S,6S)-6-[(2S)-3-dodecanoyloxy-2-tetradecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C35H66O12S (710.4275)

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoate

C41H59O8P (710.3947)

[(2R)-2-decanoyloxy-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] (E)-pentadec-9-enoate

C34H63O13P (710.4006)

[3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropyl] (4E,7E)-hexadeca-4,7-dienoate

C38H63O10P (710.4159)

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

C38H63O10P (710.4159)

[(2R,3R,6R)-6-[(2S)-2-decanoyloxy-3-hexadecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C35H66O12S (710.4275)

[(2S,3S,6S)-3,4,5-trihydroxy-6-[(2S)-2-pentadecanoyloxy-3-undecanoyloxypropoxy]oxan-2-yl]methanesulfonic acid

C35H66O12S (710.4275)

[(2R)-1-decanoyloxy-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropan-2-yl] (E)-pentadec-9-enoate

C34H63O13P (710.4006)

[(2S,3S,6S)-6-[(2S)-3-decanoyloxy-2-hexadecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C35H66O12S (710.4275)

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C41H59O8P (710.3947)

[(2R)-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-2-undecanoyloxypropyl] (E)-tetradec-9-enoate

C34H63O13P (710.4006)

[3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropyl] (E)-hexadec-7-enoate

C38H63O10P (710.4159)

[(2R,3R,6R)-3,4,5-trihydroxy-6-[(2S)-3-pentadecanoyloxy-2-undecanoyloxypropoxy]oxan-2-yl]methanesulfonic acid

C35H66O12S (710.4275)

[(2S,3S,6S)-6-[(2S)-2-dodecanoyloxy-3-tetradecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C35H66O12S (710.4275)

[(2R)-1-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (E)-tetradec-9-enoate

C34H63O13P (710.4006)

[3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropyl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C38H63O10P (710.4159)

[(2S,3S,6S)-6-[(2S)-2,3-di(tridecanoyloxy)propoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C35H66O12S (710.4275)

[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C38H63O10P (710.4159)

[(2S)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C38H63O10P (710.4159)

SQDG(26:0)

C35H66O12S (710.4275)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

SMGDG O-25:2;O

C34H62O13S (710.3911)

SMGDG O-26:1

C35H66O12S (710.4275)

SQDG 25:1;O

C34H62O13S (710.3911)

SQDG 26:0

C35H66O12S (710.4275)

SQDG 27:7

C36H54O12S (710.3336)

SQMG 28:7

C37H58O11S (710.37)

DGGA 29:4;O

C38H62O12 (710.4241)

PA 22:2/13:4;O2

C38H63O10P (710.4159)

PA 22:4/12:3;O3

C37H59O11P (710.3795)

PA 22:5/12:2;O3

C37H59O11P (710.3795)

PA 34:7;O3

C37H59O11P (710.3795)

PA 35:6;O2

C38H63O10P (710.4159)

BMP 32:6

C38H63O10P (710.4159)

HBMP 30:7;O

C36H55O12P (710.3431)

HBMP 31:6

C37H59O11P (710.3795)

PG 16:0/12:2;O3

C34H63O13P (710.4006)

PG 18:4/13:3;O

C37H59O11P (710.3795)

PG 20:0/8:2;O3

C34H63O13P (710.4006)

PG 20:5/11:2;O

C37H59O11P (710.3795)

PG 22:5/8:3;O2

C36H55O12P (710.3431)

PG 22:6/8:2;O2

C36H55O12P (710.3431)

PG 22:6/9:1;O

C37H59O11P (710.3795)

PG 30:8;O2

C36H55O12P (710.3431)

PG 31:7;O

C37H59O11P (710.3795)

PG 10:0_22:6

C38H63O10P (710.4159)

PG 32:6

C38H63O10P (710.4159)

PI O-16:0/8:3;O2

C33H59O14P (710.3642)

PI O-24:3;O2

C33H59O14P (710.3642)

PI O-25:2;O

C34H63O13P (710.4006)

PI P-16:0/8:2;O2

C33H59O14P (710.3642)

PI P-16:0/9:1;O

C34H63O13P (710.4006)

PI P-16:1/8:1;O2

C33H59O14P (710.3642)

PI P-20:0/5:1;O

C34H63O13P (710.4006)

PI P-20:1/4:1;O2

C33H59O14P (710.3642)

PI 16:1/8:1;O

C33H59O14P (710.3642)

PI 18:0/6:2;O

C33H59O14P (710.3642)

PI 20:1/4:1;O

C33H59O14P (710.3642)

PI 24:2;O

C33H59O14P (710.3642)

PI 10:0_15:1

C34H63O13P (710.4006)

PI 11:0_14:1

C34H63O13P (710.4006)

PI 21:0/4:1

C34H63O13P (710.4006)

PI 25:1

C34H63O13P (710.4006)

(2s,3r,4s,5r)-2-{[(2r,3r,4s,5r,6r)-3,5-dihydroxy-2-methyl-6-[(1'r,2r,2's,4's,5s,7's,8'r,9's,12's,13'r,16's,18's,19's)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-16'-oloxy]oxan-4-yl]oxy}oxane-3,4,5-triol

C38H62O12 (710.4241)

2-{[4,5-dihydroxy-2-(hydroxymethyl)-6-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]oxy}oxan-3-yl]oxy}oxane-3,4,5-triol

C38H62O12 (710.4241)

(1r,5e,7s,8r,9s,10s,11s,12s,16r,17s,18r,22s,26r,27s,28s)-8-[(1z)-buta-1,3-dien-1-yl]-22,27-dihydroxy-20-(hydroxymethyl)-16,24,28-trimethyl-10-[(1e,3e,5e)-nona-1,3,5-trien-1-yl]-2,14-dioxaheptacyclo[14.13.0.0¹,¹⁷.0⁷,¹².0⁹,¹¹.0¹⁸,²⁷.0²²,²⁶]nonacosa-5,19,24-triene-3,13,23-trione

C44H54O8 (710.3818)

1-[3,5-bis({[2,6-dihydroxy-4-methoxy-3-methyl-5-(2-methylbutanoyl)phenyl]methyl})-2,4,6-trihydroxyphenyl]-2-methylbutan-1-one

C39H50O12 (710.3302)

2-methoxy-2-methyl-1-{10,11,20-trihydroxy-4,6,12,17,17-pentamethyl-18-[(3,4,5-trihydroxyoxan-2-yl)oxy]-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-yl}propyl acetate

C38H62O12 (710.4241)

4-[(1r)-1-{3-hexanoyl-2,4,6-trihydroxy-5-[(1r)-1-(2-hydroxy-3,3,5,5-tetramethyl-4,6-dioxocyclohex-1-en-1-yl)-2-methylpropyl]phenyl}-3-methylbutyl]-5-hydroxy-2,2,6,6-tetramethylcyclohex-4-ene-1,3-dione

C41H58O10 (710.403)

3a-hydroxy-7-[(3-hydroxy-4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-11a-methyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthrene-9a-carbaldehyde

C36H54O14 (710.3513)

(1s,3r,6s,7s,8s,9s,10s,11s,14s,16s)-6-acetyl-14-{[(2r,4r,5r,6r)-5-{[(2s,3r,4r,5r,6r)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-8-hydroxy-7,11-dimethyl-2-oxapentacyclo[8.8.0.0¹,³.0³,⁷.0¹¹,¹⁶]octadecan-9-yl acetate

C37H58O13 (710.3877)

22-epirhodeasapogenin-1-o-α-l-rhamnopyra-nosyl(1→2)-β-d-xylopyranoside

C38H62O12 (710.4241)

{"Ingredient_id": "HBIN003727","Ingredient_name": "22-epirhodeasapogenin-1-o-\u03b1-l-rhamnopyra-nosyl(1\u21922)-\u03b2-d-xylopyranoside","Alias": "NA","Ingredient_formula": "C38H62O12","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7005","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

5-ene-methyl-7,12-didehydroxy-cholate-3-o-α-l-rhamnopyranosyl-(1→4)-β-d-glucurono-pyranoside

C37H58O13 (710.3877)

{"Ingredient_id": "HBIN011525","Ingredient_name": "5-ene-methyl-7,12-didehydroxy-cholate-3-o-\u03b1-l-rhamnopyranosyl-(1\u21924)-\u03b2-d-glucurono-pyranoside","Alias": "NA","Ingredient_formula": "C37H58O13","Ingredient_Smile": "CC1C(C(C(C(O1)OC2C(C(C(OC2C(=O)O)OC3CCC4(C5CCC6(C(C5CC=C4C3)CCC6C(C)CCC(=O)OC)C)C)O)O)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT15242","TCMID_id": "6798","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

Aspafilioside A

C38H62O12 (710.4241)

{"Ingredient_id": "HBIN017087","Ingredient_name": "Aspafilioside A","Alias": "aspafilioside a","Ingredient_formula": "C38H62O12","Ingredient_Smile": "CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CCC6C5(CCC(C6)OC7C(C(C(C(O7)CO)OC8C(C(C(CO8)O)O)O)O)O)C)C)C)OC1","Ingredient_weight": "710.89","OB_score": "16.77451607","CAS_id": "72947-73-0","SymMap_id": "SMIT05900","TCMID_id": "1860","TCMSP_id": "MOL003898","TCM_ID_id": "NA","PubChem_id": "44445743","DrugBank_id": "NA"}

Aspafilioside A_qt

C38H62O12 (710.4241)

{"Ingredient_id": "HBIN017088","Ingredient_name": "Aspafilioside A_qt","Alias": "NA","Ingredient_formula": "C38H62O12","Ingredient_Smile": "NA","Ingredient_weight": "710.89","OB_score": "17.65549914","CAS_id": "72947-73-0","SymMap_id": "SMIT05901","TCMID_id": "NA","TCMSP_id": "MOL003899","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

asparanin b3

C38H62O12 (710.4241)

{"Ingredient_id": "HBIN017107","Ingredient_name": "asparanin b3","Alias": "NA","Ingredient_formula": "C38H62O12","Ingredient_Smile": "CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CCC6C5(CCC(C6)OC7C(C(C(CO7)OC8C(C(C(C(O8)CO)O)O)O)O)O)C)C)C)OC1","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1871","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

asparanin b4

C38H62O12 (710.4241)

{"Ingredient_id": "HBIN017108","Ingredient_name": "asparanin b4","Alias": "NA","Ingredient_formula": "C38H62O12","Ingredient_Smile": "CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CCC6C5(CCC(C6)OC7C(C(C(C(O7)CO)O)O)OC8C(C(C(CO8)O)O)O)C)C)C)OC1","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1872","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

atractyloside h

C32H54O17 (710.3361)

{"Ingredient_id": "HBIN017308","Ingredient_name": "atractyloside h","Alias": "NA","Ingredient_formula": "C32H54O17","Ingredient_Smile": "CC12CCC(CC1C(=C)C(C(C2)OC3C(C(C(C(O3)COC4C(C(CO4)(CO)O)O)O)O)O)O)C(C)(C)OC5C(C(C(C(O5)CO)O)O)O","Ingredient_weight": "710.76","OB_score": "NA","CAS_id": "126054-84-0","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "6486","PubChem_id": "101831406","DrugBank_id": "NA"}

(1s,3br,4r,5as,7r,9s,9as,9br,11as)-4,9-bis(acetyloxy)-1-[(3s,5r,6s)-5,6-dihydroxy-6-(2-hydroxypropan-2-yl)oxan-3-yl]-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

C41H58O10 (710.403)

3a-hydroxy-7-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-11a-methyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthrene-9a-carboxylic acid

C36H54O14 (710.3513)

(1s,5e,7r,8s,9r,10r,11r,12r,16s,17r,18s,22r,26s,27r,28r)-8-[(1z)-buta-1,3-dien-1-yl]-22,27-dihydroxy-20-(hydroxymethyl)-16,24,28-trimethyl-10-[(1e,3e,5e)-nona-1,3,5-trien-1-yl]-2,14-dioxaheptacyclo[14.13.0.0¹,¹⁷.0⁷,¹².0⁹,¹¹.0¹⁸,²⁷.0²²,²⁶]nonacosa-5,19,24-triene-3,13,23-trione

C44H54O8 (710.3818)

n-[(3s,9r,12s,13r,16s,19s,22s)-19-benzyl-9-[(2s)-butan-2-yl]-11,18-dihydroxy-16-isopropyl-13,20-dimethyl-2,8,15,21-tetraoxo-14-oxa-1,7,10,17,20-pentaazatricyclo[20.3.0.0³,⁷]pentacosa-10,17-dien-12-yl]ethanimidic acid

C37H54N6O8 (710.4003)

(6r)-6-[(1r,2r,3as,3br,7r,8s,9as,9br,11ar)-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-2-methyl-5-oxoheptan-2-yl acetate

C38H62O12 (710.4241)

4-(1-{3-hexanoyl-2,4,6-trihydroxy-5-[1-(2-hydroxy-3,3,5,5-tetramethyl-4,6-dioxocyclohex-1-en-1-yl)-2-methylpropyl]phenyl}-3-methylbutyl)-5-hydroxy-2,2,6,6-tetramethylcyclohex-4-ene-1,3-dione

C41H58O10 (710.403)

2-{[4,5-dihydroxy-6-(hydroxymethyl)-2-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]oxy}oxan-3-yl]oxy}oxane-3,4,5-triol

C38H62O12 (710.4241)

(1s,2s,3as,3bs,5ar,7r,9as,9br,11ar)-3a-hydroxy-7-{[(2r,4s,5s,6r)-4-hydroxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl formate

C36H54O14 (710.3513)

β-k-strophanthin

C36H54O14 (710.3513)

methyl 9-hydroxy-7-(2-{[9-hydroxy-7-(2-methoxy-2-oxoethylidene)-1,4a,8-trimethyl-10-oxo-decahydro-1h-phenanthren-2-yl]oxy}-2-oxoethylidene)-1,4a,8-trimethyl-10-oxo-decahydrophenanthrene-1-carboxylate

C41H58O10 (710.403)

[(1r,2s,3r,4s,5r,6s,8r,9r,10r,16s,17r,18s)-6-(acetyloxy)-11-ethyl-8,9-dihydroxy-4,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-[(3s)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate

C38H50N2O11 (710.3414)

n-[19-benzyl-11,18-dihydroxy-16-isopropyl-13,20-dimethyl-2,8,15,21-tetraoxo-9-(sec-butyl)-14-oxa-1,7,10,17,20-pentaazatricyclo[20.3.0.0³,⁷]pentacosa-10,17-dien-12-yl]ethanimidic acid

C37H54N6O8 (710.4003)

(2s,3r,4s,5r)-2-{[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2's,7's,8'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]oxy]oxan-3-yl]oxy}oxane-3,4,5-triol

C38H62O12 (710.4241)

(1s,5e,7e,9r,10r,11s,12r,13z,18s,19r,20s,24r,28s,29r,30r)-10-ethenyl-24,29-dihydroxy-22-(hydroxymethyl)-18,26,30-trimethyl-11-[(1e,3e,5e)-nona-1,3,5-trien-1-yl]-2,16-dioxahexacyclo[16.13.0.0¹,¹⁹.0⁹,¹².0²⁰,²⁹.0²⁴,²⁸]hentriaconta-5,7,13,21,26-pentaene-3,15,25-trione

C44H54O8 (710.3818)

3a-hydroxy-7-[(4-hydroxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl formate

C36H54O14 (710.3513)

(1r,3as,3br,5as,7s,9as,9bs,11ar)-3a,5a-dihydroxy-7-{[(2r,4r,5s,6r)-4-methoxy-6-methyl-5-{[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-11a-methyl-1-(5-oxo-2h-furan-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthrene-9a-carbaldehyde

C36H54O14 (710.3513)

(2s,3r,4s,5r)-2-{[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(1'r,2r,2's,4's,5s,7's,8'r,9's,12's,13's,16's,18'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]oxy]oxan-3-yl]oxy}oxane-3,4,5-triol

C38H62O12 (710.4241)

(1s,5e,7e,9z,11r,13r,14s,15z,20s,21r,22s,26r,30s,31r,32r)-26,31-dihydroxy-24-(hydroxymethyl)-20,28,32-trimethyl-13-[(1e,3e,5e)-nona-1,3,5-trien-1-yl]-2,18-dioxahexacyclo[18.13.0.0¹,²¹.0¹¹,¹⁴.0²²,³¹.0²⁶,³⁰]tritriaconta-5,7,9,15,23,28-hexaene-3,17,27-trione

C44H54O8 (710.3818)

8-(buta-1,3-dien-1-yl)-22,27-dihydroxy-20-(hydroxymethyl)-16,24,28-trimethyl-10-(nona-1,3,5-trien-1-yl)-2,14-dioxaheptacyclo[14.13.0.0¹,¹⁷.0⁷,¹².0⁹,¹¹.0¹⁸,²⁷.0²²,²⁶]nonacosa-5,19,24-triene-3,13,23-trione

C44H54O8 (710.3818)

(1s,5e,7s,8s,9r,10r,11s,12r,16s,17r,18s,22r,26s,27r,28r)-9-ethenyl-22,27-dihydroxy-20-(hydroxymethyl)-16,24,28-trimethyl-11-[(1e,3e,5e,7e)-undeca-1,3,5,7-tetraen-1-yl]-2,14-dioxaheptacyclo[14.13.0.0¹,¹⁷.0⁷,¹².0⁸,¹⁰.0¹⁸,²⁷.0²²,²⁶]nonacosa-5,19,24-triene-3,13,23-trione

C44H54O8 (710.3818)

(1r)-1-[(1s,4r,5r,6r,8r,10r,11r,12s,13r,16r,18s,21r)-10,11-dihydroxy-4,6,12,17,17-pentamethyl-18-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-yl]-2-hydroxy-2-methylpropyl acetate

C38H62O12 (710.4241)

5,6-dihydroxy-6-(2-hydroxy-3a,6,6,9b,11a-pentamethyl-10-oxo-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-1-yl)-2-methylheptan-2-yl acetate

C38H62O12 (710.4241)

(1r,3as,3br,5as,7s,9as,9bs,11ar)-3a,5a-dihydroxy-7-{[(2s,3r,4r,6r)-3-methoxy-6-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-11a-methyl-1-(5-oxo-2h-furan-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthrene-9a-carbaldehyde

C36H54O14 (710.3513)

10-ethenyl-24,29-dihydroxy-22-(hydroxymethyl)-18,26,30-trimethyl-12-(nona-1,3,5-trien-1-yl)-2,16-dioxaheptacyclo[16.13.0.0¹,¹⁹.0⁹,¹⁴.0¹¹,¹³.0²⁰,²⁹.0²⁴,²⁸]hentriaconta-5,7,21,26-tetraene-3,15,25-trione

C44H54O8 (710.3818)

1-{3-[(3-{[2,6-dihydroxy-4-methoxy-3-methyl-5-(3-methylbutanoyl)phenyl]methyl}-2,4,6-trihydroxy-5-(3-methylbutanoyl)phenyl)methyl]-2,4-dihydroxy-6-methoxy-5-methylphenyl}-3-methylbutan-1-one

C39H50O12 (710.3302)

methyl (1s,4ar,4bs,7e,8r,8as,9r,10ar)-7-(2-{[(1s,2s,4ar,4bs,7e,8r,8as,9r,10as)-9-hydroxy-7-(2-methoxy-2-oxoethylidene)-1,4a,8-trimethyl-10-oxo-decahydro-1h-phenanthren-2-yl]oxy}-2-oxoethylidene)-9-hydroxy-1,4a,8-trimethyl-10-oxo-decahydrophenanthrene-1-carboxylate

C41H58O10 (710.403)

(2s,3r,4s,5r)-2-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1'r,2r,2's,4's,5r,7's,8'r,9's,12's,13's,16's,18'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]oxy]oxan-3-yl]oxy}oxane-3,4,5-triol

C38H62O12 (710.4241)

[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-6-(acetyloxy)-11-ethyl-8,9-dihydroxy-4,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-[(3s)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate

C38H50N2O11 (710.3414)

(1r,5e,7e,9r,10r,11r,12r,13z,18r,19s,20r,24s,28r,29s,30s)-10-ethenyl-24,29-dihydroxy-22-(hydroxymethyl)-18,26,30-trimethyl-11-[(1e,3e,5e)-nona-1,3,5-trien-1-yl]-2,16-dioxahexacyclo[16.13.0.0¹,¹⁹.0⁹,¹².0²⁰,²⁹.0²⁴,²⁸]hentriaconta-5,7,13,21,26-pentaene-3,15,25-trione

C44H54O8 (710.3818)

4,9-bis(acetyloxy)-1-[5,6-dihydroxy-6-(2-hydroxypropan-2-yl)oxan-3-yl]-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

C41H58O10 (710.403)

(1r,3as,5as,7s,9as,11ar)-7-{[(2r,5r)-6-({[(3r,6s)-4,6-dihydroxy-2-methyloxan-3-yl]oxy}methyl)-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy}-3a,5a-dihydroxy-11a-methyl-1-(5-oxo-2h-furan-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthrene-9a-carbaldehyde

C36H54O14 (710.3513)

(1r,3r,4r,7r,9r,10r,12r,13r,19r,21r,23s)-23-{[(2r,3r,4r,5s,6s)-4,5-dihydroxy-3-methoxy-6-methyloxan-2-yl]oxy}-4,9-dihydroxy-12,19-dimethyl-5-oxo-6,25,26-trioxatetracyclo[19.3.1.1⁴,⁷.1¹⁰,¹³]heptacosa-15,17-dien-3-yl butanoate

C37H58O13 (710.3877)

6-(2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,10h,11h-cyclopenta[a]phenanthren-1-yl)-6-hydroxy-2-methyl-5-oxoheptan-2-yl acetate

C38H62O12 (710.4241)

1-(10,11-dihydroxy-4,6,12,17,17-pentamethyl-18-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-yl)-2-hydroxy-2-methylpropyl acetate

C38H62O12 (710.4241)

(1s)-2-methoxy-2-methyl-1-[(1s,4r,5r,6r,8r,10s,11r,12s,13r,16s,18s,20s,21s)-10,11,20-trihydroxy-4,6,12,17,17-pentamethyl-18-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-yl]propyl acetate

C38H62O12 (710.4241)

9-ethenyl-22,27-dihydroxy-20-(hydroxymethyl)-16,24,28-trimethyl-11-(undeca-1,3,5,7-tetraen-1-yl)-2,14-dioxaheptacyclo[14.13.0.0¹,¹⁷.0⁷,¹².0⁸,¹⁰.0¹⁸,²⁷.0²²,²⁶]nonacosa-5,19,24-triene-3,13,23-trione

C44H54O8 (710.3818)

10-ethenyl-24,29-dihydroxy-22-(hydroxymethyl)-18,26,30-trimethyl-11-(nona-1,3,5-trien-1-yl)-2,16-dioxahexacyclo[16.13.0.0¹,¹⁹.0⁹,¹².0²⁰,²⁹.0²⁴,²⁸]hentriaconta-5,7,13,21,26-pentaene-3,15,25-trione

C44H54O8 (710.3818)

2-[(3,5-dihydroxy-2-methyl-6-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-16'-oloxy}oxan-4-yl)oxy]oxane-3,4,5-triol

C38H62O12 (710.4241)

(5s,6r)-6-[(1r,2r,3as,3bs,7s,9ar,9br,11ar)-2-hydroxy-3a,6,6,9b,11a-pentamethyl-10-oxo-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-1-yl]-5,6-dihydroxy-2-methylheptan-2-yl acetate

C38H62O12 (710.4241)

[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-4-(acetyloxy)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-[(3s)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate

C38H50N2O11 (710.3414)

(1r,3as,3br,5ar,7s,9ar,9bs,11ar)-3a-hydroxy-7-{[(2r,3r,4r,5s,6r)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-11a-methyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthrene-9a-carbaldehyde

C36H54O14 (710.3513)

3a,5a-dihydroxy-7-[(3-methoxy-6-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-11a-methyl-1-(5-oxo-2h-furan-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthrene-9a-carbaldehyde

C36H54O14 (710.3513)

2-methyl 4a-(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2s,4ar,6as,6br,8ar,9r,10r,11s,12as,12br,13r,14bs)-10,11,13-trihydroxy-9-(hydroxymethyl)-2,6a,6b,9,12a-pentamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-2,4a-dicarboxylate

C37H58O13 (710.3877)

4,9-bis(acetyloxy)-1-[5-(1,2-dihydroxy-2-methylpropyl)-2-hydroxyoxolan-3-yl]-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

C41H58O10 (710.403)

[(5r,6s,8r,9s,13s)-4-(acetyloxy)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate

C38H50N2O11 (710.3414)

(1s,5e,7e,9r,10r,11r,12s,13r,14r,18s,19r,20s,24r,28s,29r,30r)-10-ethenyl-24,29-dihydroxy-22-(hydroxymethyl)-18,26,30-trimethyl-12-[(1e,3e,5e)-nona-1,3,5-trien-1-yl]-2,16-dioxaheptacyclo[16.13.0.0¹,¹⁹.0⁹,¹⁴.0¹¹,¹³.0²⁰,²⁹.0²⁴,²⁸]hentriaconta-5,7,21,26-tetraene-3,15,25-trione

C44H54O8 (710.3818)

2-methoxy-2-methyl-1-{10,11,14-trihydroxy-4,6,12,17,17-pentamethyl-18-[(3,4,5-trihydroxyoxan-2-yl)oxy]-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-yl}propyl acetate

C38H62O12 (710.4241)

(5s,6r)-6-[(1r,2r,3ar,3bs,7s,9ar,9br,11ar)-2-hydroxy-3a,6,6,9b,11a-pentamethyl-10-oxo-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-1-yl]-5,6-dihydroxy-2-methylheptan-2-yl acetate

C38H62O12 (710.4241)

2-({[4-(15-ethoxy-4,8,10,12-tetramethyl-3,5,7,9,11,13,16-heptaoxaoctadecan-6-yl)tricyclo[3.2.1.1¹,³]nonan-7-yl]methoxy}carbonyl)benzene-1,3-dicarboxylic acid

C36H54O14 (710.3513)

(4r,4as,5r,6s,8as,9ar)-4-{[(4r,4as,5r,6s,8as,9ar)-4-hydroxy-3,4a,5-trimethyl-6-{[(2e)-2-methylbut-2-enoyl]oxy}-2-oxo-4h,5h,6h,7h,8h,9h,9ah-naphtho[2,3-b]furan-8a-yl]oxy}-8a-hydroxy-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h,9h,9ah-naphtho[2,3-b]furan-6-yl 3-methylbut-2-enoate

C40H54O11 (710.3666)

[6-(acetyloxy)-11-ethyl-8,9-dihydroxy-4,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate

C38H50N2O11 (710.3414)

(1s)-2-methoxy-2-methyl-1-[(1s,4r,5r,6r,8r,10r,11r,12s,13r,14s,16r,18s,21r)-10,11,14-trihydroxy-4,6,12,17,17-pentamethyl-18-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-yl]propyl acetate

C38H62O12 (710.4241)

(2r,3r,4s,5s,6r)-2-{[(2r,3r,4ar,6r,8ar)-3-hydroxy-8a-methyl-4-methylidene-6-(2-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}propan-2-yl)-octahydronaphthalen-2-yl]oxy}-6-({[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)oxane-3,4,5-triol

C32H54O17 (710.3361)

(2r)-1-[3,5-bis({2,6-dihydroxy-4-methoxy-3-methyl-5-[(2r)-2-methylbutanoyl]phenyl}methyl)-2,4,6-trihydroxyphenyl]-2-methylbutan-1-one

C39H50O12 (710.3302)

(2s,3r,4s,5s)-2-{[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(1'r,2r,2's,4's,5s,7's,8'r,9's,12's,13's,16's,18'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]oxy]oxan-3-yl]oxy}oxane-3,4,5-triol

C38H62O12 (710.4241)

(1s,5e,7e,9r,10r,11r,12r,13r,14r,18s,19r,20s,24r,28s,29r,30r)-10-ethenyl-24,29-dihydroxy-22-(hydroxymethyl)-18,26,30-trimethyl-12-[(1e,3e,5e)-nona-1,3,5-trien-1-yl]-2,16-dioxaheptacyclo[16.13.0.0¹,¹⁹.0⁹,¹⁴.0¹¹,¹³.0²⁰,²⁹.0²⁴,²⁸]hentriaconta-5,7,21,26-tetraene-3,15,25-trione

C44H54O8 (710.3818)

(2s,3r,4s,5r)-2-{[(2r,3r,4s,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1'r,2r,2's,4's,5r,7's,8'r,9's,12's,13's,16's,18'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]oxy]oxan-3-yl]oxy}oxane-3,4,5-triol

C38H62O12 (710.4241)

[(1s,2s,4s,5r,6s,8r,9r,10r,13s,16s,18s)-6-(acetyloxy)-11-ethyl-8,9-dihydroxy-4,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-[(3s)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate

C38H50N2O11 (710.3414)

(2r,3r,4s,5s,6r)-2-[(1'r,2r,2's,4's,5s,7's,8'r,9's,12's,13's,16's,18'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]oxy]-6-({[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}methyl)oxane-3,4,5-triol

C38H62O12 (710.4241)

[(1r,2s,3r,4s,5r,6s,8r,9r,10r,13s,16s,17r,18s)-6-(acetyloxy)-11-ethyl-8,9-dihydroxy-4,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-[(3s)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate

C38H50N2O11 (710.3414)

(2s,3r,4s,5r)-2-{[(2r,3r,4s,5r,6r)-3,5-dihydroxy-2-methyl-6-[(1'r,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,16's,18's,19's)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-16'-oloxy]oxan-4-yl]oxy}oxane-3,4,5-triol

C38H62O12 (710.4241)

(1s,5e,7s,8s,9s,10r,11s,12r,16s,17r,18s,22r,26s,27r,28r)-9-ethenyl-22,27-dihydroxy-20-(hydroxymethyl)-16,24,28-trimethyl-11-[(1e,3e,5e,7e)-undeca-1,3,5,7-tetraen-1-yl]-2,14-dioxaheptacyclo[14.13.0.0¹,¹⁷.0⁷,¹².0⁸,¹⁰.0¹⁸,²⁷.0²²,²⁶]nonacosa-5,19,24-triene-3,13,23-trione

C44H54O8 (710.3818)

8a-hydroxy-4-({4-hydroxy-3,4a,5-trimethyl-6-[(2-methylbut-2-enoyl)oxy]-2-oxo-4h,5h,6h,7h,8h,9h,9ah-naphtho[2,3-b]furan-8a-yl}oxy)-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h,9h,9ah-naphtho[2,3-b]furan-6-yl 3-methylbut-2-enoate

C40H54O11 (710.3666)

(5e,7e)-26,31-dihydroxy-24-(hydroxymethyl)-20,28,32-trimethyl-13-(nona-1,3,5-trien-1-yl)-2,18-dioxahexacyclo[18.13.0.0¹,²¹.0¹¹,¹⁴.0²²,³¹.0²⁶,³⁰]tritriaconta-5,7,9,15,23,28-hexaene-3,17,27-trione

C44H54O8 (710.3818)

(6r)-6-[(1r,2r,3as,3br,7r,8s,9ar,9br,11ar)-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-2-methyl-5-oxoheptan-2-yl acetate

C38H62O12 (710.4241)